Mesoblast Limited
MEOBF
$1.37
-$0.25-15.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.58M | 1.58M | 1.26M | 1.26M | 1.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58M | 1.58M | 1.26M | 1.26M | 1.69M |
| Cost of Revenue | -3.28M | -3.28M | 10.84M | 10.84M | 3.93M |
| Gross Profit | 4.86M | 4.86M | -9.58M | -9.58M | -2.23M |
| SG&A Expenses | 8.59M | 8.59M | 6.07M | 6.07M | 5.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 21.50K | 21.50K | 40.50K | 40.50K | -451.50K |
| Total Operating Expenses | 11.57M | 11.57M | 16.95M | 16.95M | 14.99M |
| Operating Income | -9.99M | -9.99M | -15.69M | -15.69M | -13.29M |
| Income Before Tax | -23.86M | -23.86M | -27.75M | -27.75M | -16.32M |
| Income Tax Expenses | 106.00K | 106.00K | -44.50K | -44.50K | -51.00K |
| Earnings from Continuing Operations | -23.97M | -23.97M | -27.71M | -27.71M | -16.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.97M | -23.97M | -27.71M | -27.71M | -16.27M |
| EBIT | -9.99M | -9.99M | -15.69M | -15.69M | -13.29M |
| EBITDA | -9.45M | -9.45M | -15.26M | -15.26M | -12.78M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.14B | 1.14B | 1.12B | 1.12B | 875.37M |
| Average Diluted Shares Outstanding | 1.14B | 1.14B | 1.12B | 1.12B | 875.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
